Alvocidib: all 49 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyTerminatedNCT03969420Phase 2Results posted
• Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).CompletedNCT03298984Phase 1Results posted
• Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedNCT02520011Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01349972Phase 2Results posted
• Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By SurgeryCompletedNCT00991952Phase 2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00795002Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedNCT00445341Phase 1/2Results posted
• Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2Results posted
• Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic CancerCompletedNCT00331682Phase 2Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098371Phase 2Results posted
• Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00083122Phase 2Results posted
• Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedNCT00058240Phase 1/2Results posted
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03441555Phase 1
• Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT01076556Phase 1
• Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00735930Phase 1
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT00470197Phase 1
• Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)CompletedNCT00464633Phase 2
• Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT00377104Phase 1
• Vorinostat and Alvocidib in Treating Patients With Advanced Solid TumorsCompletedNCT00324480Phase 1
• Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
• Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT00112684Phase 1
• Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaTerminatedNCT00101231Phase 1
• Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By SurgeryCompletedNCT00098579Phase 1
• Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedNCT00094978Phase 1
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid TumorsCompletedNCT00080990Phase 1
• Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00079352Phase 1
• Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid TumorsCompletedNCT00072436Phase 1
• Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic MalignanciesTerminatedNCT00070239Phase 1
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic CancerCompletedNCT00047307Phase 1
• Flavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00047203Phase 2
• Combination Chemotherapy in Treating Patients With Advanced Solid TumorsCompletedNCT00046917Phase 1
• Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00042874Phase 1
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
• Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00023894Phase 2
• Combination Chemotherapy in Treating Patients With Advanced CancerCompletedNCT00021073Phase 1
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney CancerCompletedNCT00016939Phase 2
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00005974Phase 2
• Flavopiridol in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00005971Phase 2
• Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell LymphomaCompletedNCT00005074Phase 2
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• Flavopiridol in Treating Patients With Recurrent Prostate CancerCompletedNCT00003256Phase 2
• Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00003039Phase 2

← Alvocidib overview